STOCK TITAN

ARDELYX (ARDX) SEC Filings

ARDX NASDAQ

Ardelyx, Inc. filings document a commercial-stage biopharmaceutical company with U.S. product revenue from IBSRELA and XPHOZAH and development activity centered on tenapanor and NHE3 inhibition. Form 8-K reports cover quarterly operating results, preliminary product sales, cash and investment updates, Regulation FD presentation materials, and other material-event disclosures tied to the company’s commercial and clinical programs.

Ardelyx proxy materials describe annual meeting proposals, director elections, say-on-pay matters, auditor ratification, executive compensation, board structure, and stockholder voting mechanics. Additional current reports record officer appointments, executive transitions, transition and separation agreements, compensatory arrangements, governance matters, and disclosure controls relevant to the company’s public-company reporting obligations.

Rhea-AI Summary

Ardelyx, Inc. Chief Financial Officer Susan Hohenleitner had 11,537 shares withheld for income-tax obligations on November 19, 2026, in connection with net settlement of time-based restricted stock unit awards. The withholding was not an open-market sale. The reported transaction price was $3.06 per share. She directly held 215,983 shares after the transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Ardelyx, Inc. Senior Vice President and Chief Accounting Officer Joseph James Reilly had 3,755 shares withheld by the issuer for income-tax obligations on November 19, 2026, in connection with net settlement of time-based restricted stock unit awards; the transaction was not an open-market sale. The reported price was $3.06 per share. Reilly directly held 145,086 shares after the transaction, including 2,987 shares acquired through the employee stock purchase plan on August 31, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

John E. Bishop, Ardelyx, Inc.’s Chief Technical and Quality Officer, reported that the issuer withheld 6,413 shares of common stock for tax obligations on November 19, 2026, at a reported $3.06 per share. The withholding related to income-tax withholding and remittance obligations in the net settlement of time-based restricted stock unit awards; it was not an open-market sale. Bishop directly held 310,682 shares after the transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Ardelyx, Inc. reported that Chief Human Resources Officer James Parker Brady had 4,973 common shares withheld for income-tax obligations on November 19, 2026. The issuer withheld the shares to meet income-tax withholding and remittance obligations tied to net settlement of certain time-based restricted stock unit awards; the transaction was not an open-market sale. Brady directly held 240,957 shares afterward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Ardelyx, Inc. Chief Business Officer Mike Kelliher had 7,319 shares withheld for income-tax obligations on November 19, 2026, by the issuer in connection with net settlement of certain time-based restricted stock unit awards; the transaction was not an open-market sale. He directly held 342,341 shares afterward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Ardelyx, Inc. President & CEO Michael Raab had 55,376 common shares withheld on November 19, 2026, at $3.06 per share to satisfy income-tax withholding and remittance obligations in connection with net settlement of time-based restricted stock unit awards; this was not an open-market sale. His reported direct holdings after the transaction were 1,567,416 shares, including 3,000 shares acquired under the employee stock purchase plan on August 31, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Ardelyx, Inc. (ARDX) is the issuer for which six reporting persons state beneficial ownership of its common stock. Tang Capital Management, LLC and Kevin Tang each report 14,336,247 shares, or 5.7%, with shared voting and dispositive power and zero sole voting or dispositive power. The statement’s event date is November 9, 2026.

Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc. separately report 2,663,183, 4,892,410, 3,350,677 and 3,429,977 shares, respectively, each with shared voting and dispositive power. Tang Capital Management, LLC is general partner of the first two entities. Kevin Tang is TCM’s manager and chief executive officer of the latter two.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
ownership
-
Rhea-AI Summary

Ardelyx, Inc. reported third-quarter 2026 revenue of $127.7 million, up 16% year over year, with net product sales of $125.5 million, up 19%. IBSRELA sales rose 23% to $96.3 million, while XPHOZAH sales rose 7% to $29.2 million. For the nine months ended September 30, revenue was $343.0 million, up 22%, and net product sales were $337.0 million, up 28%.

Net loss was $0.7 million for the quarter versus $1.0 million a year earlier; nine-month net loss was $55.1 million versus $61.2 million. Net cash used in operations was $36.5 million for nine months, compared with $63.4 million. Research and development expense increased 47% to $71.5 million over nine months, reflecting increased clinical trial activity, including the Phase 3 trial of tenapanor for chronic idiopathic constipation.

Cash, cash equivalents and short-term investments totaled $285.3 million at September 30, 2026, versus $264.7 million at December 31, 2025. Term-loan principal outstanding was $250.0 million; the future payment obligation, excluding interest, was $260.8 million due July 1, 2030. Ardelyx said continued lack of Medicare Part D coverage for XPHOZAH will materially reduce its revenue-growth pace versus pre-ESRD PPS expectations. ACCEL enrollment is complete, with topline data expected in the second half of 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.58%
Tags
quarterly report
-
Rhea-AI Summary

Ardelyx, Inc. (ARDX) reported third-quarter 2026 total product revenue of $125.5 million, up 19% year over year. IBSRELA revenue was $96.3 million, up 23%, and XPHOZAH revenue was $29.2 million, up 7%. Cash, cash equivalents and short-term investments totaled $285.3 million as of September 30, 2026, compared with $264.7 million as of December 31, 2025.

Net loss was $0.7 million, compared with $1.0 million a year earlier; total operating expenses were $119.1 million, up 17%. Ardelyx reiterated 2026 revenue guidance of between $350 million and $370 million for IBSRELA and between $110 million and $120 million for XPHOZAH, and operating expenses below $500 million. Enrollment in the Phase 3 ACCEL trial for chronic idiopathic constipation was completed ahead of schedule, with topline data expected in the second half of 2027. The USPTO notified Ardelyx that it will issue a patent covering commercial formulations of both products on November 10, 2026; the patent expires December 6, 2041.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.58%
Tags
current report
Rhea-AI Summary

ARDELYX, INC. (ARDX) reported that Chief Financial Officer Susan Hohenleitner sold 1,558 shares of common stock on 2026-08-21 at a weighted-average price of $3.8569 per share. According to the filing, this was an automatic sell-to-cover triggered by vesting of RSUs to pay withholding taxes, executed in multiple trades between $3.648 and $3.984. After these tax-related sales, she directly holds 227,520 shares of ARDX common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
insider

FAQ

How many ARDELYX (ARDX) SEC filings are available on StockTitan?

StockTitan tracks 147 SEC filings for ARDELYX (ARDX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for ARDELYX (ARDX)?

The most recent SEC filing for ARDELYX (ARDX) was filed on November 20, 2026.